HER2 Low Advanced BC: Module

CME

Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2024

Expiration: January 25, 2025

Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Activity

Progress
1 2
Course Completed

Conclusions

In summary, the HER2-low breast cancer categorization represents a paradigm shift in the way in which patients with HR-positive metastatic breast cancer are treated, especially now that T-DXd has become a standard of care for patients with HER2-low disease. Even with the improved efficacy of T-DXd compared with standard chemotherapy regimens, it is important to remain cognizant of the unique potential toxicities associated with T-DXd use in clinical practice. In particular, it is important to be aware that nausea can arise, and the application of a 3-drug prophylaxis makes a tremendous difference in controlling this adverse event. Also, ILD can emerge and this is a toxicity of particular interest, given that it can be severe, although rarely, and careful monitoring with routine imaging is highly recommended. 

With several ADCs in the clinical pipeline, we will need to clearly define how to optimally sequence these agents for patients with HER2-low breast cancer in the future.